Neurogene Inc. (NGNE)

NASDAQ: NGNE · Real-Time Price · USD

17.05

1.65 (10.71%)

At close: May 02, 2025, 3:59 PM

17.49

2.58%

After-hours: May 02, 2025, 05:50 PM EDT

10.71% (1D)

Bid	12.98
Market Cap	243.17M
Revenue (ttm)	925K
Net Income (ttm)	-75.14M
EPS (ttm)	-4.28
PE Ratio (ttm)	-3.98
Forward PE	-2.07
Analyst	Buy

Ask	17.49
Volume	183,222
Avg. Volume (20D)	279,627
Open	15.98
Previous Close	15.40
Day's Range	15.54 - 17.44
52-Week Range	6.88 - 74.49
Beta	1.47

About NGNE

Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York....

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Mar 7, 2014

Employees 107

Stock Exchange NASDAQ

Ticker Symbol NGNE

Website https://www.neurogene.com

Full Company Profile

Analyst Forecast

According to 5 analyst ratings, the average rating for NGNE stock is "Buy." The 12-month stock price forecast is $66, which is an increase of 287.10% from the latest price.

Stock Forecasts

Why Price Moved

5 months ago

-42.58%

Neurgogene shares are trading lower after the comp... Unlock content with Pro Subscription

5 months ago

-44.08%

Neurogene shares are trading lower. The company issued interim efficacy data from its first four low-dose pediatric participants in NGN-401 gene therapy clinical trial for Rett Syndrome.

News

5 days ago · businesswire.com

Neurogene Announces Upcoming Oral Presentation on Monitoring and Treatment to Reverse Rare Complication of High Dose Gene Therapy at the ASGCT Annual Meeting

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, tod...

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (NASDAQ: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, tod...

2 months ago · accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE

NEW YORK, NY / ACCESS Newswire / February 5, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Neurogene Inc. ("Neurogene" or the "Company") (NASDAQ:NGNE). Such investors are advi...